A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer
TL;DR: Novel attempts at the prevention of high-grade serous ovarian cancer and treatment strategies for two distinct entities in epithelial ovarian cancer are discussed, which represent a paradigm shift not only for treatment but also for prevention, which previously had not been considered achievable.
Journal ArticleDOI
Phase I trial of patupilone plus carboplatin in patients with advanced cancer
M. E. Gore,Stan B. Kaye,Amit M. Oza,C. Keyzor,L. Pyle,R. Pereno,I. Sklenar,Sara Zaknoen,A. Johri +8 more
TL;DR: Patupilone is a natural epothilone, which is a microtubule-targeting cytotoxic that has demonstrated clinical activity in taxane-sensitive and resistant tumors and produces synergistic in this paper.
Journal ArticleDOI
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
Fabian Trillsch,Sven Mahner,Beyhan Ataseven,Rebecca Asher,Nanda R. Aryal,Coraline Dubot,Andrew R Clamp,Richard T. Penson,Amit M. Oza,Amnon Amit,Tomasz Huzarski,Antonio Casado,Giovanni Scambia,Michael Friedlander,Nicoletta Colombo,Keiichi Fujiwara,Gabe S. Sonke,Hannelore Denys,Elizabeth S. Lowe,Chee Khoon Lee,Eric Pujade-Lauraine +20 more
TL;DR: Olaparib has significantly improved outcome and patient-centered endpoints in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer (PSOC) as mentioned in this paper .
Journal ArticleDOI
Randomized trial of oral cyclophosphamide (C) with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma.
Shivaani Kummar,Amit M. Oza,Gini F. Fleming,Daniel C. Sullivan,David R. Gandara,Charles Erlichman,Miguel A. Villalona-Calero,Robert J. Morgan,Alice P. Chen,Jiuping Jay Ji,Deborah Allen,Chih-Jian Lih,Seth M. Steinberg,P. Mickey Williams,Barbara A. Conley,James H. Doroshow +15 more
TL;DR: A randomized multicenter trial comparing the response rate (RR) of V and C to the RR of C alone in patients with deleterious BRCA mutations and recurrent ovarian, or primary peritoneal, fallopian tube or high-grade serous ovarian cancer.
Journal ArticleDOI
ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma
TL;DR: A previous proof-of-concept phase II trial of the Wee1 inhibitor adavosertib in uterine serous carcinoma demonstrated evidence of durable clinical activity as discussed by the authors.